Keyphrases
Prostate Cancer
100%
Enzalutamide
100%
Evidence-based Review
100%
Androgen Receptor
45%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
27%
Phase II Study
18%
Castration-resistant Prostate Cancer
18%
Chemotherapy
18%
Docetaxel
9%
Phase II Trial
9%
Placebo
9%
Seizure
9%
Headache
9%
Overexpression
9%
Novel Therapies
9%
Prostate Cancer Patients
9%
Safety Profile
9%
Clinical Utility
9%
Androgen Receptor Antagonist
9%
Overall Survival
9%
Adverse Events
9%
Nave
9%
Disease Stage
9%
MEDLINE
9%
Peer-reviewed Articles
9%
Gene Promoter
9%
Median Overall Survival
9%
Optimal Combination
9%
Androgen Response Element
9%
Hot Flashes
9%
Optimal Sequence
9%
Place in Therapy
9%
Evidence Review
9%
Pharmacology, Toxicology and Pharmaceutical Science
Enzalutamide
100%
Prostate Cancer
100%
Androgen Receptor
54%
Castration Resistant Prostate Cancer
45%
Chemotherapy
18%
Overall Survival
18%
Placebo
9%
Docetaxel
9%
Headache
9%
Adverse Event
9%
Hot Flush
9%
Disease
9%
Androgen
9%